Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine (ACELLDREAM2)

The main purpose of this study is to evaluate the efficacy of regenerative therapy with expanded adipose derived stroma/stem cells, administered intramuscularly in patients with critical leg ischemia.

 

Clinical indication

Critical limb ischemia

Disease area

Cardiology/Vascular

Cell type

ASC

Autologous/allogeneic

Autologous

Route of administration

Loca/intramuscular

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

Phase II

Recruitment target

100

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

-

Website

https://www.smartpatients.com/trials/NCT01211028 (ACELLDREAM1)

 

 

 

Principal investigator: Dr. Jérome Roncalli (Toulouse University hospital, France)

EcellFrance activity: cell production (ATMP), cell potency/QC, patient immunomonitoring???

EcellFrance contact: Louis Casteilla

 

 

Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue (ACELLFIST)

The study aim is to evaluate the viability, security and tolerance of the adipose-derived mesenchymal stem cells implant (ASCs) in fistulizing Crohn's disease patients.

 

Clinical indication

Fistula Crohn disease

Disease area

Immunology

Cell type

ASC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

I/II

Recruitment target

20

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

-

Website

-

 

 

 

Principal investigator: Dr. Jérome Roncalli (Toulouse University hospital, France)

EcellFrance activity: cell production (ATMP), cell potency/QC

EcellFrance contact: Louis Casteilla

 

 

 A "live" implant to regenerate the cartilage (BIOCAR)

The goal of this study is to evaluate the feasibility and the safety of a therapeutic implant with a bioactive membrane of collagen and autologous bone marrow mesenchymal stem cells for the treatment of femoral cartilage lesions.

 

Clinical indication

Cartilage injuries

Disease area

Musculoskeletal

Cell type

BMSC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

Yes

Transgene

No

Activation/differentiation

No

Trial phase

I

Recruitment target

12

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

-

Website

-

 

 

 

Principal investigator: Dr Nadia Benkirane-Jessel (Strasbourg medical school, France)

EcellFrance activity: cell production (ATMP)

EcellFrance contact:  Jean-Jacques Lataillade

 

 

A phase II clinical trial of mesenchymal stem cells on organ failure during the septic shock (CHOC-MSC)

The study aims at evaluating the effects of the administration of mesenchymal stem cells on multiple-organ failures during septic shock

 

Clinical indication

Septic shock

Disease area

Infections and Infectious

Cell type

BMSC

Autologous/allogeneic

Allogeneic

Route of administration

Systemic

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

II

Recruitment target

60 (30 treated)

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

-

Website

-

 

 

 

Principal investigator: Dr. Sébastien Gibot (University hospital of Nancy, France)

EcellFrance activity: cell production (ATMP), patient immunomonitoring

EcellFrance contact:  Christian Jorgensen

 

 

Treatment of Myasthenia gravis (MG) by in vitro-preconditioned human MSCs (cMSC-MG)

Aim/objective:

 

Clinical indication

Myasthenia gravis

Disease area

Immunology

Cell type

BMSC

Autologous/allogeneic

Allogeneic

Route of administration

-

Biomaterial

No

Transgene

No

Activation/differentiation

Yes

Trial phase

Preclinical

Recruitment target

-

Year trial started

-

Trial status

-

Clinical trial ID

-

Website

-

 

 

 

Principal investigator: Dr. Sonia Berrih-Aknin (Pitié-Salpêtrière Hospital, France)

EcellFrance activity: cell production (ATMP), preclinical, cell potency/QC, patient immunomonitoring (project)

EcellFrance contact: Hélène Rouard

 

 

Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial (LYZYME)

Aim/objective:    

 

 

Clinical indication

Lyell's syndrome

Disease area

Dermatology

Cell type

ASC

Autologous/allogeneic

Allogeneic

Route of administration

Systemic

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

I/II

Recruitment target

15

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

-

Website

-

 

 

 

Principal investigator: Dr. Hélène Rouard (EcellFrance) and Dr. Saskia Oro (APHP, France)

EcellFrance activity: cell production (ATMP), cell potency/QC, patient immunomonitoring, coordination (Hélène Rouard)

EcellFrance contact: Hélène Rouard

 

 

 Systemic injection of HLA mesenchymal stem cells from intra-familial donor for the treatment of Recessive Dystrophic Epidermolysis Bullosa (MESEBDR)

 

Aim/objective

 

 

 

Clinical indication

Recessive Dystrophic Epidermolysis Bullosa

Disease area

Dermatology

Cell type

BMSC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

I

Recruitment target

6

Year trial started

Withdrawn?

Trial status

Withdrawn?

Clinical trial ID

 

Website

 

 

 

 

Principal investigator: Dr Alain Hovnanian (Necker Hospital, France)

EcellFrance activity: cell production (ATMP)

EcellFrance contact: Jean-Jacques Lataillade

 

 

Innovative intervertebral disc cell therapy: efficacy of intervertebral injection of mesenchymal stromal/stem cells in a randomized controlled phase 2 trial (MESODISC2)

In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc Disease (DDD).

 

Clinical indication

Degenerative disk disease

Disease area

Musculoskeletal

Cell type

BMSC

Autologous/allogeneic

Autologous vs allogeneic

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

II

Recruitment target

150 (100 treated)

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

 

Website

 

 

 

 

Principal investigator: Dr Christian Jorgensen (EcellFrance)

EcellFrance activity: cell production (ATMP), cell potency/QC, patient immunomonitoring, coordination (Christian Jorgensen)

EcellFrance contact: Christian Jorgensen

 

 

Phase 2 clinical trial to investigate efficacy and safety of allogeneic MSCs for the treatment of severe venous leg ulcers (METRO)

 Aim/objective

 

 

 

Clinical indication

Venous Leg Ulcers

Disease area

Podiatry

Cell type

ASC

Autologous/allogeneic

Allogeneic

Route of administration

Local

Biomaterial

Yes

Transgene

No

Activation/differentiation

No

Trial phase

II

Recruitment target

80

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

 

Website

 

 

 

 

 

 

Principal investigator: Dr Patricia Senet (APHP, France)

EcellFrance activity: cell production (ATMP), cell potency/QC, patient immunomonitoring, coordination (Luc Sensebé)

EcellFrance contact: Luc Sensebé

 

 

Mesenchymal stem cells as a vector of an optimized suicide gene to destroy human solid tumors (ONCOCYP)

Aim/objective

 

 

 

Clinical indication

Hepatocellular carcinoma

Disease area

Oncology

Cell type

BMSC

Autologous/allogeneic

allogeneic

Route of administration

Local

Biomaterial

No

Transgene

Yes

Activation/differentiation

No

Trial phase

Preclinical

Recruitment target

 

Year trial started

Unstarted

Trial status

Unstarted

Clinical trial ID

 

Website

 

 

 

 

Principal investigator: Isabelle de Waziers, Philippe Beaune (APHP, France)

EcellFrance activity: cell production (ATMP), gene modification/transfection, cell potency/QC, patient immunomonitoring

EcellFrance contact: Stéphane Roux et Jean-Jacques Lataillade

 

 

REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease unresponsive to conventional therapy (RESPINE)

Aim/objective

 

 

Clinical indication

Degenerative disc disease

Disease area

Musculoskeletal

Cell type

BMSC

Autologous/allogeneic

Allogeneic

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

IIb

Recruitment target

112

Year trial started

Unstarted (planned for october 2017)

Trial status

Unstarted

Clinical trial ID

 

Website

 

 

 

 

Principal investigator: Prof. Christian Jorgensen (ECellFrance)

EcellFrance activity: cell production (ATMP), cell potency/QC, patient immunomonitoring, coordination (Christian Jorgensen)

EcellFrance contact: Christian Jorgensen